miRNA-223-3p, miRNA- 2909 and Cytokines Expression in COVID-19 Patients Treated with Ivermectin
Rezk et al.
, miRNA-223-3p, miRNA- 2909 and Cytokines Expression in COVID-19 Patients Treated with Ivermectin
, Zagazig University Medical Journal, doi:10.21608/zumj.2021.92746.2329
Prospective 320 hospitalized moderate COVID-19+ patients in Egypt, 160 treated with ivermectin, showing lower mortality, improved recovery, and decreased cytokine expression with treatment. All patients were treated with HCQ. 7890/26-8-2020.
risk of death, 80.0% lower, RR 0.20, p = 0.50, treatment 0 of 160 (0.0%), control 2 of 160 (1.2%), NNT 80, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
risk of progression, 55.6% lower, RR 0.44, p = 0.06, treatment 8 of 160 (5.0%), control 18 of 160 (11.2%), NNT 16, 2 weeks, including deaths.
risk of no recovery, 33.4% lower, RR 0.67, p = 0.27, treatment 14 of 145 (9.7%), control 20 of 138 (14.5%), NNT 21, 4 weeks, more patients were lost to followup in the control group.
time to viral-, 27.3% lower, relative time 0.73, p = 0.01, treatment 160, control 160.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Rezk et al., 30 Oct 2021, prospective, Egypt, peer-reviewed, 4 authors, dosage 36mg days 1, 3, 6.
Abstract: Manuscript ID
miRNA-223-3p, miRNA- 2909 and Cytokines Expression in COVID-19 Patients
Treated with Ivermectin
Noha A. Rezk1 , Ashraf Elsayed Sileem2 , Doaa Mostafa Gad2 , Amr O. Khalil 3 ,
Medical Biochemistry, Faculty of Medicine, Zagazig University, Egypt.
Chest Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt;
Radiology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt;
Name noha rezk. Affiliation
Assistant Professor of
Faculty of Medicine,
Zagazig University, Egypt.
Mailing address: Medical
Faculty of Medicine,
Zagazig University, Zagazig
Background: The role of Ivermectin in improving the outcome of coronavirus
disease of 2019 (COVID-19) symptoms was reported in several studies, while its
effect on the pro-inflammatory cytokines triggering the cytokine storm is still not
Method: This study aimed to investigate the role of Ivermectin on the
proinflammatory cytokines in Covid-19 patients and correlated the results with the
expression of miR-2909, miR-223-3p. Three hundred and twenty hospitalized
patients with confirmed moderate-severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) infection were selected. The patients were divided into 2 groups:
Group I treated with the Egyptian protocol of COVID-19 including (Ivermectin
plus hydroxychloroquine). Group II was treated with the Egyptian protocol,
including hydroxychloroquine and no Ivermectin. IL-6, IL-1b, procalcitonin, and
gene expression of miR-2909, miR-223-3p, and Toll-like receptor 4 were done by
real-time Polymerase Chain Reaction (PCR).
Results : Patients treated with COVID-19 protocol including Ivermectin showed
a significant decrease of cytokines levels (IL-6, IL-1, and procalcitonin), when
compared with the other group, the cytokines levels improvement were positively
correlated with miR-2029 expression and negatively correlated with the expression
of miR-223-3p. Moderate ill COVID-19 patients treated with Ivermectin showed a
significant decline in mortality rate and duration of hospital stay.
Conclusion: Ivermectin is an effective drug in improving the outcome of SARSCoV-2 patients with a significant decrease in mortality rate through decreasing
cytokines expression via controlling miR-2029, miR-233-3p expressions.
Keywords: SARS-CoV-2; Ivermectin; miR-223-3p; miR-2029; Covid-19;
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC
provide treatment protocols.